Program
tulisokibart
Also written as “Tulisokibart”, “IV Tulisokibart” and “SC Tulisokibart”.
Its studies are mostly in Crohn Disease · Colitis, Ulcerative · Panuveitis · Sarcoidosis, Pulmonary · Axial Spondyloarthritis, led by Merck.
Drug pageTulisokibart: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 1710 open or running | phase 3since Sep 18, 2023 | Dec 9, 2020 | Feb 17, 2027phase 2 · NCT07486960 |
- Named in Merck’s own pipeline as
tulisokibart (MK-7240)
, phase 3, as of Nov 2, 2026 (source).
Also a collaborator on its studies: PPD, Part of Thermo Fisher Scientific, Celerion and Altasciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Dec 9, 2020.
- Feb 27, 2022Phase 2 study in Scleroderma, DiffuseNCT05270668 · 154 enrolled · United States, Argentina, Australia and more
- Apr 1, 2022Phase 1 study in HealthyNCT05354349 · 49 enrolled · United States
- Jul 21, 2022Named tulisokibartINNProposed as its International Nonproprietary Name in WHO's List 127
- Sep 18, 2023Phase 3 study in Colitis, UlcerativeNCT06052059 · 1,109 enrolled · United States, Argentina, Australia and more
- May 21, 2024Phase 3 study in Crohn DiseaseNCT06430801 · 1,200 planned · United States, Australia, Austria and more
- Aug 16, 2024Phase 1 study in HealthyNCT06575595 · 60 enrolled · United States
- Oct 18, 2024Phase 3 study in Crohn DiseaseNCT06651281 · 1,380 planned · United States, Czechia, France and more
- Feb 11, 2025Phase 1 study in Colitis, UlcerativeNCT06829225 · 48 enrolled · China
- Apr 30, 2025Phase 2 study in Hidradenitis SuppurativaNCT06956235 · 149 enrolled · United States, Argentina, Australia and more
- Aug 14, 2025Phase 2 study in Radiographic Axial SpondyloarthritisNCT07133633 · 315 enrolled · United States, Brazil, Canada and more
- Sep 9, 2025Phase 2 study in Arthritis, RheumatoidNCT07176390 · 185 enrolled · United States, Canada, Chile and more
- Feb 5, 2026Phase 1 study in HealthyNCT07405177 · 330 enrolled · Australia
- Mar 19, 2026Phase 2 study in Arthritis, PsoriaticNCT07486960 · 140 enrolled · United States, Canada, Chile and more
- Sep 30, 2026Phase 2 study in PanuveitisNCT07861074 · 87 planned · United States, Canada
- Oct 5, 2026Phase 2 study in Sarcoidosis, PulmonaryNCT07867938 · 158 planned · United States
Ahead
- Feb 17, 2027Primary completion: phase 2 study in Arthritis, PsoriaticNCT07486960
- Mar 29, 2027Primary completion: phase 2 study in Radiographic Axial SpondyloarthritisNCT07133633
- Oct 30, 2028Primary completion: phase 3 study in Crohn DiseaseNCT06430801
- Jun 5, 2029Primary completion: phase 2 study in PanuveitisNCT07861074
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07867938Sarcoidosis, Pulmonary · United States | 2 | Recruiting | Oct 5, 2029 | 158 |
| NCT07861074Panuveitis · United States, Canada | 2 | Recruiting | Jun 5, 2029 | 87 |
| NCT07486960Arthritis, Psoriatic · United States, Canada, Chile and more | 2 | Active, not recruiting | Feb 17, 2027 | 140 |
| NCT07405177Healthy · Australia | 1 | Completed | Sep 19, 2026 | 330 |
| NCT07176390Arthritis, Rheumatoid · United States, Canada, Chile and more | 2 | Active, not recruiting | Sep 7, 2026 | 185 |
| NCT07133633Radiographic Axial Spondyloarthritis · United States, Brazil, Canada and more | 2 | Active, not recruiting | Mar 29, 2027 | 315 |
| NCT06956235Hidradenitis Suppurativa · United States, Argentina, Australia and more | 2 | Active, not recruiting | Apr 2, 2026 | 149 |
| NCT06829225Colitis, Ulcerative · China | 1 | Completed | Nov 11, 2024 | 48 |
| NCT06651281Crohn Disease · United States, Czechia, France and more | 3 | Recruiting | Dec 17, 2037 | 1,380 |
| NCT06575595Healthy · United States | 1 | Completed | Jan 31, 2025 | 60 |
| NCT06430801Crohn Disease · United States, Australia, Austria and more | 3 | Recruiting | Oct 30, 2028 | 1,200 |
| NCT06052059Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 12, 2026 | 1,109 |
| NCT05354349Healthy · United States | 1 | Completed | Aug 31, 2022 | 49 |
| NCT05270668Scleroderma, Diffuse · United States, Argentina, Australia and more | 2 | Active, not recruiting | Apr 16, 2026 | 154 |
| NCT05013905Crohn Disease · United States, Australia, Belgium and more | 2 | Completed | Sep 23, 2022 | 55 |
| NCT04996797Colitis, Ulcerative · United States, Australia, Belgium and more | 2 | Completed | Jun 6, 2023 | 178 |
| NCT04676178Healthy · United States | 1 | Completed | Sep 23, 2021 | 69 |
How it is read
Names in the registry
- “Tulisokibart”, 12 entries
- “IV Tulisokibart”, 2 entries
- “SC Tulisokibart”, 2 entries
- “Tulisokibart Form 1”, 1 entry
- “Tulisokibart Form 2”, 1 entry
Conditions, from the studies’ own filings
- Crohn Disease, 3 studies
- Colitis, Ulcerative, 3 studies
- Panuveitis, 1 study
- Sarcoidosis, Pulmonary, 1 study
- Axial Spondyloarthritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.